Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.1K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.1K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

832
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
832
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

957
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
957
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

8.0K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Awareness of obesity's causes is not linked to less Weight-Related bias.

Scientific reports·2025
Same author

Promoting a turnaround in the management of renal disease in obese patients.

Nefrologia·2025
Same author

The Spanish GIRO Guideline: A Paradigm Shift in the Management of Obesity in Adults.

Obesity facts·2025
Same author

A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.

Kidney international·2024
Same author

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.

Diabetes care·2024
Same author

Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.

Frontiers in endocrinology·2023

Related Experiment Video

Updated: Nov 22, 2025

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.6K

Visual field progression in patients with severe glaucoma.

Eugenio J Maul1, Alan Kastner2, Jimena Schmidt2

  • 1Department of Ophthalmology, School of Medicine, Pontificia Universidad Católica de Chile, Ave. Apoquindo 3990 Suite 708, PC:7550112, Santiago, Chile. emauld@gmail.com.

Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie
|January 8, 2021
PubMed
Summary

The cumulative 5-year risk of progression for severe glaucoma patients is 14.6%. This study assessed severe glaucoma progression, finding a 2.9% annual incidence over five years.

Keywords:
GlaucomaHumphreyProgressionSevereVisual field damage

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.6K
Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping
07:11

Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping

Published on: December 8, 2023

2.1K

Related Experiment Videos

Last Updated: Nov 22, 2025

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.6K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.6K
Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping
07:11

Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping

Published on: December 8, 2023

2.1K

Area of Science:

  • Ophthalmology
  • Clinical Research
  • Glaucoma Studies

Background:

  • Glaucoma is a leading cause of irreversible blindness.
  • Assessing progression in severe glaucoma is crucial for patient management.
  • Understanding cumulative risk aids in predicting long-term visual outcomes.

Purpose of the Study:

  • To evaluate the cumulative risk of disease progression in eyes with severe-stage glaucoma.
  • To quantify the rate of visual field and visual acuity decline in this patient cohort.

Main Methods:

  • Retrospective observational study including 143 eyes from 119 patients with severe glaucoma (mean deviation ≤ -20 dB).
  • Progression defined by visual field loss (≥ 2 dB MD) or visual acuity decline (≥ 2 lines) over consecutive tests.
  • Kaplan-Meier survival analysis used to determine cumulative incidence of progression.

Main Results:

  • The mean follow-up period was 4.9 years.
  • Twenty-three eyes (16.1%) reached the progression endpoint.
  • The cumulative 5-year risk of progression was estimated at 14.6% (95% CI: 6.1-22.2%).

Conclusions:

  • Severe glaucoma patients experience a cumulative progression incidence of 2.9% per year over the initial 5 years.
  • These findings are comparable to progression rates reported in other glaucoma severity stages.
  • The study highlights the ongoing risk of vision loss even in advanced glaucoma.